MCP: Keeping tabs on protein variants
Perhaps you have seen a time-lapse video of a busy city sidewalk. As people come and go, they blur together into a crowd with no distinguishing features. You could count the number of people pushing strollers in each frame, but it might be hard to tell how long one parent has been circling the same block with a colicky baby.

As proteins are made and destroyed in a cell, they tend to blur together too. Many proteomics studies measure with precision the number of copies of each protein species but not how long each one lasts. In a new paper in the journal Molecular & Cellular Proteomics, researchers in Bernard Kuster’s lab at the Technical University of Munich report a new approach to determining the lifespan of a great many proteins, and their alternative isoforms, in large data sets.
“Plenty of research has demonstrated that cancer, neurodegenerative diseases, age-related diseases and even aging per se are associated with altered lifespans of single proteins or a global dysregulation of the cellular recycling machinery,” said lead author Jana Zecha. She compares a cell in which proteins are continuously made and destroyed to “a tiny protein production and recycling machinery.” With colleagues, Zecha set out to measure this factory’s output, determining the rates of production and destruction of many different proteins.
The researchers combined two techniques for telling samples apart by their mass: stable isotope labeling by amino acids in cell culture, or SILAC for short, and tandem mass tag labeling, or TMT. The primary SILAC label enabled a pulse-chase experiment, a way of measuring how much of a new amino acid is taken up after it is added to cells. By combining SILAC with TMT, the researchers could achieve high proteome coverage with high reproducibility and accurate counts of each protein. Then they looked for trends over time. For example, a protein’s rate of synthesis can be measured by how much of the new SILAC label appears over time in its spectrum, and degradation is measured by how much the old label disappears.
Other scientists previously had combined the SILAC and TMT methods, but this data set gave an unusually thorough look at protein lifetimes. The researchers found substantial variability among splice variants of proteins, which no one had yet measured in a data set of this size. Because two splice variants from the same gene have many peptides in common, a data set with many measurements at the peptide level was required.
The approach could offer a better way of understanding the basic biology of disease states with altered protein turnover. The researchers also are interested in modifications occurring after translation that may alter turnover rates.
“A proteomewide measurement of turnover rates of modified peptides is the next logical step for us,” Zecha said.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Teaching AI to listen
A computational medicine graduate student reflects on building natural language processing tools that extract meaning from messy clinical notes — transforming how we identify genetic risk while redefining what it means to listen in science.

Early lipid changes drive retinal degeneration in Zellweger spectrum disorder
Lipid profiling in a rare disease mouse model reveals metabolic shifts and inflammation in the retinal pigment epithelium — offering promising biomarker leads to combat blindness.

How sugars shape Marfan syndrome
Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.

What’s in a diagnosis?
When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.